Associated tags: Google Images, Diagnosis, Radiology, Patient, Cancer, Medical imaging, MRI, Health, Genetic testing, Adrian Dixon, Genetics, Medicine, Liver disease, MYGN, Association for Molecular Pathology v. Myriad Genetics, Inc., American College, FDA, Breast cancer, Mammography, Pharmaceutical industry, SALT
Locations: UNITED STATES
Liver disease,
Pelvis,
Cancer,
Intelligence,
Head,
Brain,
Prostate,
Body image disturbance,
MRI,
Paul Simonon,
Patient,
Protocol,
AI,
Health,
Mental health,
Medical imaging SCOTTSDALE, Ariz., June 15, 2023 /PRNewswire/ -- SimonMed Imaging ("SimonMed"), one of the largest outpatient medical imaging providers and radiology practices in the United States, today announced the launch of simonONE directly to patients to provide affordable, fast, non-invasive whole body MRI screening.
Key Points:
- SCOTTSDALE, Ariz., June 15, 2023 /PRNewswire/ -- SimonMed Imaging ("SimonMed"), one of the largest outpatient medical imaging providers and radiology practices in the United States, today announced the launch of simonONE directly to patients to provide affordable, fast, non-invasive whole body MRI screening.
- A simonONE then reviews results with the patient in a telehealth consultation and works with the patient to establish a personalized action plan.
- "Through simonONE, we are combining over 20 years of clinical expertise in whole body imaging, cutting edge artificial intelligence, and advanced medical technology to deliver a powerful exam at lower cost and greater speed," said Dr. John Simon, Founder and Chief Executive Officer of SimonMed Imaging and simonONE.
- simonONE has significantly reduced the scan time and cost using innovations in AI to become the nationwide leader in accessibility, both in terms of value and footprint.
Retrieved on:
Wednesday, April 12, 2023
Society,
Myriad Genetics,
Radiology,
Health equity,
Risk assessment,
Woman,
MYGN,
SALT,
Google Images,
MRI,
Adrian Dixon,
Genetics,
Patient,
Risk,
Medicine,
Genetic testing,
Diagnosis,
Association for Molecular Pathology v. Myriad Genetics, Inc.,
American College,
Health,
FDA,
Breast cancer,
Cancer,
Mammography,
Medical imaging,
Pharmaceutical industry,
Myriad SALT LAKE CITY, April 12, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and SimonMed® Imaging , one of the largest independent outpatient medical imaging providers and physician radiology practices in the United States, today announced the planned launch of a new hereditary cancer assessment program that combines diagnostic imaging, genetic risk assessment utilizing MyRisk® with RiskScore® and patient education.
Key Points:
- SALT LAKE CITY, April 12, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and SimonMed® Imaging , one of the largest independent outpatient medical imaging providers and physician radiology practices in the United States, today announced the planned launch of a new hereditary cancer assessment program that combines diagnostic imaging, genetic risk assessment utilizing MyRisk® with RiskScore® and patient education.
- For more than 30 years, Myriad and SimonMed have worked independently to help millions of patients understand their health and well-being through genetic testing and diagnostic imaging.
- The collaboration will bring together the strengths of Myriad’s risk assessment resources and hereditary cancer test, MyRisk with RiskScore, and SimonMed’s deep expertise in the medical imaging space.
- Myriad and SimonMed will begin a phased rollout of the program in early May 2023 to patients at select SimonMed women’s imaging sites.
Data management,
Other Health,
Technology,
Radiology,
Practice Management,
Oncology,
Managed care,
General Health,
Medical devices,
Hospitals,
Other Technology,
Biotechnology,
Software,
Networks,
Health,
Medical physics,
Image processing,
Medical imaging,
Radiology,
IntelePeer,
Medical specialty,
Applied sciences,
Academic disciplines,
SimonMed,
IntelePeer,
SIMONMED,
INTELEPEER We selected IntelePeer for their impressive track record and expertise, says SimonMed CIO Duleep Wikramanayke.
Key Points:
- We selected IntelePeer for their impressive track record and expertise, says SimonMed CIO Duleep Wikramanayke.
- The companys solutions not only improve processes but also help in keeping overhead as low as possible.
- Before implementation, SimonMeds voice and data costs totaled approximately $5.4 million.
- SimonMed Imaging is the largest physician owned outpatient radiology practice in the United States and specializes in all major medical fields of medical imaging.
Retrieved on:
Wednesday, August 19, 2020
Technology,
Medical devices,
Software,
Practice Management,
Hardware,
Radiology,
General Health,
Health,
Data management,
Oncology,
Anatomy,
Prostate cancer,
Histopathology,
RTT,
Magnetic resonance imaging,
Prostate,
Draft:Laser focal therapy,
CorTechs Labs,
SimonMed The arrival of RSI-MRI+ for Prostate into the SimonMed network marks an important step in our ability to accurately detect prostate cancer using the latest AI capabilities, said Dr. John Simon, MD, Chief executive officer of SimonMed.
Key Points:
- The arrival of RSI-MRI+ for Prostate into the SimonMed network marks an important step in our ability to accurately detect prostate cancer using the latest AI capabilities, said Dr. John Simon, MD, Chief executive officer of SimonMed.
- I expect RSI-MRI+ to become standard technology across U.S. imaging centers, and transform prostate cancer detection and patient care.
- RSI-MRI+ for Prostate is FDA-cleared advanced imaging software that supports improved PCa detection for a more accurate diagnosis.
- This integration of our latest AI software expands the already-extensive deployment of our other AI solutions throughout the SimonMed network of imaging centers, said Chris Airriess, Ph.D., chief executive officer of CorTechs Labs.
